Our top pick for
Vaxxinity Inc is a biotechnology business based in the US. Vaxxinity shares (VAXX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxxinity employs 89 staff and has a trailing 12-month revenue of around $49,000.
|Latest market close||$1.90|
|52-week range||$1.51 - $22.77|
|50-day moving average||$2.17|
|200-day moving average||$3.93|
|Wall St. target price||$15.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.36|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-29)||-6.86%|
|1 month (2022-09-07)||-11.63%|
|3 months (2022-07-07)||0.53%|
|6 months (2022-04-07)||-55.40%|
|1 year (2021-10-03)||N/A|
|2 years (2020-10-03)||N/A|
|3 years (2019-10-03)||N/A|
|5 years (2017-10-03)||N/A|
|Gross profit TTM||$-1,871,000|
|Return on assets TTM||-67.12%|
|Return on equity TTM||-146.38%|
|Market capitalisation||$249.5 million|
TTM: trailing 12 months
We're not expecting Vaxxinity to pay a dividend over the next 12 months.
You may also wish to consider:
Vaxxinity, Inc. , a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas. .
Find out how to buy OTC stocks and compare brokers who offer access to OTC Markets.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.